Abstract Number: 23 • 2016 ACR/ARHP Annual Meeting
Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis
Background/Purpose: The prevalence and characteristics of patients with nonalcoholic fatty liver disease (NAFLD) have not been well characterized in the RA population. The purpose of…Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…Abstract Number: 565 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Gastrointestinal Tolerance in Patients with Rheumatoid Arthritis and Methotrexate Daily Doses
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. We reported the liver safety with daily dose of MTX1. Weekly doses of MTX…Abstract Number: 2561 • 2016 ACR/ARHP Annual Meeting
A Novel Pharmacological Action of MTX on RA Fibroblast-like Synoviocytes Via Circadian Clock Genes
Background/Purpose: The circadian rhythm is disrupted in patients with rheumatoid arthritis (RA), and we have shown that tumor necrosis factor(TNF)-ƒ¿ inhibits the expression of circadian…Abstract Number: 645 • 2016 ACR/ARHP Annual Meeting
Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
Background/Purpose: Current guidelines consider MTX as initial gold standard treatment for patients (pts) with RA. They also propose various strategies for MTX inadequate responders, among…Abstract Number: 2637 • 2016 ACR/ARHP Annual Meeting
Clinical Trials Aiming to Prevent the Development of Rheumatoid Arthritis Cannot Detect Prevention without Adequate Risk Stratification; A Trial Performed in UA-Patients As Example
Background/Purpose: Prevention of rheumatoid arthritis (RA) was the aim of several clinical trials performed in undifferentiated arthritis (UA). Overall these trials had negative results. As…Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting
Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…Abstract Number: 861 • 2016 ACR/ARHP Annual Meeting
Efficacy of Methotrexate in Giant Cell Arteritis
Background/Purpose: Prospective trials evaluating methotrexate (MTX) as adjunct immunosuppression in giant cell arteritis (GCA) have provided evidence of a modest benefit for reducing risk of…Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…Abstract Number: 958 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…Abstract Number: 3090 • 2016 ACR/ARHP Annual Meeting
Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A novel automated quantification method for RA MRI-detected pathology using statistical shape…Abstract Number: 1204 • 2016 ACR/ARHP Annual Meeting
Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology that causes inflammation and irreversible damage in joints and other organs. Methotrexate (MTX) is…Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…Abstract Number: 1302 • 2016 ACR/ARHP Annual Meeting
Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort
Background/Purpose: disease activity score in 28 joints; Methods: Data-sets of 80 RA patients from the REMISSION-plus study cohort who fulfilled the following criteria were retrospectively…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 16
- Next Page »